Axsome Thera (AXSM) Stock Price, Quote & News

Company Profile

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptak...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 332 3241

Fax: 212 320 0245

Website: www.axsome.com

Address:

One World Trade Center, 29th Floor, New York, United States

Vakeshka Aug. 24 at 3:48 PM

$AXSM "H.C Wainwright Analyst Ram Selvaraju reaffirms Buy on Axsome, Maintaining $290 Price Target Amid Solid Execution...due to a combination of factors related to operating performance and growth outlook. He notes that second-quarter revenue modestly exceeded expectations, management slightly raised full-year 2026 sales guidance, and the company holds sufficient cash and access to debt to fund operations until anticipated profitability in the first half of 2027, supporting confidence in the business trajectory. He also emphasizes that the recent share price weakness creates a favorable entry point, as current results do not yet capture the potential from AUVELITY’s launch in Alzheimer’s disease–related agitation. In his view, AUVELITY’s differentiated safety and tolerability profile versus Rexulti, strong early prescription trends—especially among older patients—and broad payer coverage underpin meaningful upside, justifying the reaffirmed $290 price target and Buy recommendation.

1 · Reply

pi22dv7 Aug. 24 at 12:27 PM

$AXSM Tiring, another low volume drag down week? Common AXSM wake up.

1 · Reply

Uncle_Baby_Billy Aug. 24 at 11:04 AM

$AXSM

2 · Reply

Kenzo71 Aug. 24 at 4:59 AM

$AXSM Earlier this summer, when AXSM’s share price was hovering around $250, the January 2028 $380 calls were trading for around $25. In retrospect, getting this type of option premium seems more than reasonable assuming you would’ve been happy letting your shares be called away for $380 plus $25 call option premium = $405/share. I passed at the time because I was greedy, believing that an EU deal together with profitability in 1Q 2027 could send the share price well over $400. Perhaps a more pragmatic approach should’ve been built around the perspective of whether $400 would’ve been a share price that I would’ve been happy with. Today, I believe $400 would’ve been a satisfactory price for me to give up my shares. I would’ve had a 10 bagger and I have other stocks that I’ve been following where I could deploy additional capital. My point is be greedy, but also be pragmatic.

3 · Reply

Kenzo71 Aug. 23 at 8:24 PM

$AXSM I am really tempted to sell some December $180 cash covered puts for approximately $6.80. The option currently has a delta of around .20 suggesting an 80% probability of expiring worthless. If one believes that the Auvelity launch for ADA is going well and that growing evidence to that effect will be presented at the upcoming investor conferences and during the November earnings conference call, then the share price should stabilize above $200 and regain momentum upward.

1 · Reply

Vakeshka Aug. 23 at 11:43 AM

$AXSM this might be due to rebalancing as Axsome graduated from the Russel Microcap to Russel 1000 index, but a good indicator either way. "BlackRock Inc. bought a new position in Axsome Therapeutics, Inc. during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 3,103,708 shares of the company's stock, valued at approximately $759,695,000. BlackRock Inc. owned about 6.03% of Axsome Therapeutics at the end of the most recent reporting period..."

1 · Reply

Vakeshka Aug. 23 at 6:28 AM

$AXSM "Deutsche Bank AG purchased a new position in Axsome Therapeutics, Inc during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 86,466 shares of the company's stock, valued at approximately $21,164,000. Deutsche Bank AG owned about 0.17% of Axsome Therapeutics at the end of the most recent quarter. Great Lakes Advisors LLC bought a new stake in Axsome Therapeutics, Inc. in the second quarter. The institutional investor bought 6,730 shares of the company's stock, valued at approximately $1,647,000. Emerald Investment Advisers LLC purchased a new position during the 2nd quarter. The institutional investor purchased 28,630 shares of the company's stock, valued at approximately $7,008,000. "

0 · Reply

Live2ride Aug. 21 at 5:25 PM

$AXSM Please no fireside chats. Already down $50 bucks. 😁

2 · Reply

Mike826_1999 Aug. 21 at 4:16 PM

$AXSM Upcoming conferences, maybe some updates!

4 · Reply

chuckL4 Aug. 21 at 2:54 PM

$AXSM With options expiration today, we might see increased volatility as the bulls and bears fight over the strike prices in a low liquidity stock. Thankfully the script numbers seem to be back in nice growth mode which should lend strong support to the stock

0 · Reply

Market Cap	10.88B
Revenue (ttm)	638.50M
Net Income (ttm)	-183.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-28.69%
Debt to Equity Ratio	1.42

Volume	94,347
Avg Vol	913,654
Day's Range	N/A - N/A
Shares Out	52.38M
Stochastic %K	9%
Beta	0.65
Analysts	Strong Sell
Price Target	$277.05